A
AQST
Aquestive Therapeutics
4.660
+0.165+3.67%After Hours: 4.650 -0.010 -0.21%18:45 08/21 EDT
OPEN/PREV CLOSE4.540/4.495
TODAY RANGE4.520-4.720
VOL2.02M
MARKET CAP584.88M
52 WEEK RANGE2.930-7.55
AVG VOL (3M)2.49M
% TURNOVER1.60%
TURNOVER--
P/E (TTM)-7.1781
% RANGE4.45%
EPS(TTM)-0.6492
P/E(FORWARD)-8.8762
P/B-10.3372
BVPS-0.4508
DIVIDEND--
P/S12.77
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP561.99M
SHARES OUTSTANDING125.51M
NEXT EARNINGS11/03-11/09
FREE FLOAT120.60M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·2d ago
Aquestive Therapeutics: Potential Catalyst On The Horizon
NASDAQ·2d ago
Aquestive (AQST) Q2 2026 Earnings Call Transcript
TipRanks·08/13 12:20
Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Aquestive Therapeutics (AQST)
NASDAQ·08/11 21:25
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
TipRanks·08/11 20:35
Aquestive Advances Anaphylm Program and Q2 2026 Results
TipRanks·08/11 20:10
Aquestive Therapeutics backs FY26 revenue view $46M-$50M, consensus $50.51M
Dow Jones·08/11 20:04
*Aquestive Therapeutics Full-Yr 2026 Fincl Guidance Remains Unchanged >AQST
Dow Jones·08/11 20:04
*Aquestive Therapeutics Backs FY Rev $46M-$50M >AQST
Dow Jones·08/11 20:03
*Aquestive Therapeutics Remains on Track to Resubmit Anaphylm NDA to the FDA in 3Q
Dow Jones·08/11 20:03
*Aquestive Therapeutics On Track to Begin ex-U.S. Filings of Anaphylm in 4Q
Seeking Alpha·08/11 20:02
Aquestive Therapeutics GAAP EPS of -$0.18 misses by $0.08, revenue of $13.82M beats by $2.26M
Same Industry
Name/Symbol
Change%
Price